GlassScriptPhysician profile
Weichi Liao
NPI 1811141583
$588.95
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $13.10.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $148.27 | 2019 | |
| Mylan Specialty L.P. | $99.85 | 2019 | |
| Sunovion Pharmaceuticals INC. | $91.69 | 2019-2020 | |
| Boston Scientific Corporation | $84.35 | 2019 | |
| Glaxosmithkline, LLC. | $54.13 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $36.61 | 2019 | |
| Amgen INC. | $31.89 | 2019 | |
| Gilead Sciences, INC. | $18.01 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.63 | 2019 | |
| Pfizer INC. | $11.52 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weichi Liao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.